✦ LIBER ✦

Present state of immunosuppressive therapy in liver transplant recipients

✍ Scribed by Russell H. Wiesner; John J. Fung

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 349 KB
Volume: 17
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.22410

No coin nor oath required. For personal study only.

✦ Synopsis

Key Points

Our increasing understanding of the signaling pathways and cellular interactions in transplant immunobiology has facilitated targeted strategies using novel immunosuppressive agents. 2. The pattern of immunosuppressive drug use in the United States continues to change, and the changes include the use of antibody induction therapy and the agents used in maintenance therapy. 3. The driving forces behind the development of new immunosuppressive regimens are the long-term complications of current immunosuppressive regimens (particularly renal dysfunction and metabolic disturbances).

📜 SIMILAR VOLUMES

Increased thrombin generation in liver t

Increased thrombin generation in liver transplant recipients: Does immunosuppressive therapy play a role?

✍ Marco Senzolo; Maria T. Sartori; Kryssia Rodriguez-Castro; Paolo Simioni; Valeri 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

Immunosuppression in HCV-positive liver

Immunosuppression in HCV-positive liver transplant recipients: Pandora's box?

✍ Olivier Boillot; Jérôme Dumortier 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

Withdrawal of immunosuppression in liver

Withdrawal of immunosuppression in liver allograft recipients

✍ Padbury, Robert T.A. ;Toogood, Giles J. ;McMaster, Paul 📂 Article 📅 1998 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 85 KB

S trategies to minimize the long-term side effects of immunosuppression in liver transplant recipients have included the uniform reduction of all agents in double-or triple-therapy regimens, selective discontinuation of individual agents of such regimens, and the complete withdrawal of all long-term

Outcomes of acute rejection after interf

Outcomes of acute rejection after interferon therapy in liver transplant recipients

✍ Sammy Saab; Denise Kalmaz; Nupoor A. Gajjar; Jonathan Hiatt; Francisco Durazo; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 1 views

Interferon alfa has been increasingly used against recurrent hepatitis C (HCV) disease in post-liver transplant (LT) recipients. A serious potential adverse effect is acute rejection. We reviewed our experience using interferonbased therapy (interferon or pegylated interferon with or without ribavir

Effects of different immunosuppressive r

Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients

✍ R.C. Verdonk; E.B. Haagsma; M.R. Jonker; L.I.H. Bok; J.H. Zandvoort; J.H. Kleibe 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB 👁 1 views

## Background: Regulatory T-cells (Treg) are natural suppressors of autoimmunity. Previous studies indicate that immunosuppressive drugs, especially calcineurin-inhibitors, may interfere with Treg homeostasis. Inflammatory bowel disease (IBD) can relapse or develop de novo after liver transplantati

Treatment of hepatitis C in liver transp

Treatment of hepatitis C in liver transplant recipients

✍ Fredric D. Gordon; Paul Kwo; Hugo E. Vargas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Recurrent hepatitis C after liver transplantation is a universal phenomenon. Graft reinfection occurs rapidly; once it is established, allograft cirrhosis and decompensation rapidly ensue in many patients. Treatment with pegylated interferon plus ribavirin is the standard of care among nontransplant